Hepatitis B News and Research

Latest Hepatitis B News and Research

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona.

21 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Entire HCV lifecycle can be recapitulated in murine cells

A US study presented today at The International Liver CongressTM 2012 demonstrates that the entire HCV lifecycle can be recapitulated in murine cells, implying that HCV permissive mouse models could soon be developed.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

NALFD patients with modest alcohol intake are half as likely to develop NASH

People with nonalcoholic fatty liver disease (NALFD) who consume alcohol in modest amounts - no more than one or two servings per day - are half as likely to develop hepatitis as non-drinkers with the same condition, reports a national team of scientists led by researchers at the University of California, San Diego School of Medicine.

20 Apr 2012

Childhood obesity positively associated with HCC in adulthood

Childhood obesity is a widespread global epidemic and in parallel with non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease among children. New data presented today at the International Liver Congress- 2012 furthers this concern by showing that childhood obesity is positively linked with developing hepatocellular carcinoma (HCC) - the most common form of liver cancer - in adulthood.

19 Apr 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Two studies show true impact of liver disease across Europe

Two studies presented at the International Liver Congress- 2012 show the true impact that liver disease has across Europe. One highlights the financial cost of liver disease to the community and the second highlights the high mortality rates associated with cirrhosis.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.

19 Apr 2012

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Presidio Pharmaceuticals, Inc. announced results today from a Phase 1a-1b clinical trial of PPI-668, a potent, pan-genotypic HCV NS5A inhibitor being developed for the treatment of patients with chronic hepatitis C.

19 Apr 2012

Large childhood immunization campaign begins in Haiti, with support from U.S., other international partners

Haiti, the U.S. and other international partners on Monday launched "a nationwide vaccination campaign in the Caribbean country that seeks to curb or prevent infectious diseases, health officials said," the Associated Press/Fox News reports.

18 Apr 2012

Novel system for 3D reconstruction and examination of tissues at microscopic resolution

Researchers have developed a novel, easy-to-use system for three-dimensional (3D) reconstruction and examination of tissues at microscopic resolution, with the potential to significantly enhance the study of normal and disease processes, particularly those involving structural changes. The new approach, using conventional histopathological methods, is described in the May issue of The American Journal of Pathology.

17 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

Panel discussion on personalized medicine at USciences

Advances in fields such as genetics and genomics have created new opportunities for personalized medicine applications in clinical practice and the healthcare delivery. This integration raises important questions about how personalized medicine can best help patients without increasing costs and improving health outcomes.

16 Apr 2012

UM hosts symposium on next generation characterization tools for therapeutic proteins

In a concerted effort to boost regional collaboration on developing new protein drug and diagnostics, the University of Maryland (UM) School of Pharmacy has hosted the first Interdisciplinary Symposium on Next Generation Characterization Tools for Therapeutic Proteins.

16 Apr 2012

PURE Bioscience launches new disinfectant/sanitizer product

PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported the launch of the PURE Complete Cleaning, Sanitizing and Disinfecting System.

12 Apr 2012

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

Hepatitis B News and Research

Latest Hepatitis B News and Research

Sequana Medical's ALFApump System safe and effective in managing ascites

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data provides hope for HCV non-responders

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Entire HCV lifecycle can be recapitulated in murine cells

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

NALFD patients with modest alcohol intake are half as likely to develop NASH

Childhood obesity positively associated with HCC in adulthood

EASL publishes new clinical practice guideline on ALD

Two studies show true impact of liver disease across Europe

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Large childhood immunization campaign begins in Haiti, with support from U.S., other international partners

Novel system for 3D reconstruction and examination of tissues at microscopic resolution

UTHealth researcher studies novel cell therapy to prevent GVHD

Panel discussion on personalized medicine at USciences

UM hosts symposium on next generation characterization tools for therapeutic proteins

PURE Bioscience launches new disinfectant/sanitizer product

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in